ABUS vs VTR · P/E 5.4, rev $6.2M vs P/E 149, rev $4.92B
Arbutus Biopharma Corp (ABUS) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the ABUS and VTR stock pages for the full models.
Not investment advice.